
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="3D96E088809558D300E0880002D1EF74.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Hematological Oncology">
<meta name="citation_title" content="Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience">
<meta name="citation_author" content="Robin Noel">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Catalina Montes de Oca">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Patrick Sfumato">
<meta name="citation_author_institution" content="Department of Clinical Research and Innovation – Biostatistics and Methodology Unit, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Anne Calleja">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Aude Collignon">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Ferdinand Villetard">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Jean Marc Schiano de Collela">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Frédéric Benizri">
<meta name="citation_author_institution" content="Pharmacy Department, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Pilar Dutari">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Cécile Castoldi">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Faezeh Izadifar‐Legrand">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Luca Inchiappa">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Catherine Evans">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Gabriel Brisou">
<meta name="citation_author_institution" content="Department of Hematology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Lenaig Mescam">
<meta name="citation_author_institution" content="Department of Pathology, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_author" content="Vincent Camus">
<meta name="citation_author_institution" content="Department of Hematology, Centre Henri Becquerel, Rouen, France">
<meta name="citation_author" content="Thibaut Reichert">
<meta name="citation_author_institution" content="Department of Nuclear Medicine, Institut Paoli Calmettes, Marseille, France">
<meta name="citation_publication_date" content="2025 Apr 13">
<meta name="citation_volume" content="43">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="e70060">
<meta name="citation_doi" content="10.1002/hon.70060">
<meta name="citation_pmid" content="40221881">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/pdf/HON-43-e70060.pdf">
<meta name="description" content="Immunochemotherapy has demonstrated high cure rates in primary mediastinal large B‐cell lymphoma (PMBCL). Recent findings from the IELSG 37 study show that certain specific dose‐dense treatment regimens are more likely to eliminate the need for ...">
<meta name="og:title" content="Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Immunochemotherapy has demonstrated high cure rates in primary mediastinal large B‐cell lymphoma (PMBCL). Recent findings from the IELSG 37 study show that certain specific dose‐dense treatment regimens are more likely to eliminate the need for ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11993899">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/hon.70060"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/HON-43-e70060.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11993899%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11993899/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11993899/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/hon.70060" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Hematol Oncol</button></div>. 2025 Apr 13;43(3):e70060. doi: <a href="https://doi.org/10.1002/hon.70060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/hon.70060</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hematol%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Hematol%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Noel%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Robin Noel</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Robin Noel</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Noel%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Robin Noel</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Oca%20CM%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Catalina Montes de Oca</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Catalina Montes de Oca</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Oca%20CM%22%5BAuthor%5D" class="usa-link"><span class="name western">Catalina Montes de Oca</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sfumato%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Patrick Sfumato</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Patrick Sfumato</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Clinical Research and Innovation – Biostatistics and Methodology Unit, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sfumato%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Patrick Sfumato</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Calleja%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Anne Calleja</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Anne Calleja</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Calleja%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anne Calleja</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Collignon%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Aude Collignon</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Aude Collignon</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Collignon%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aude Collignon</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Villetard%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ferdinand Villetard</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Ferdinand Villetard</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Villetard%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Ferdinand Villetard</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schiano%20de%20Collela%20JM%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Jean Marc Schiano de Collela</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Jean Marc Schiano de Collela</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schiano%20de%20Collela%20JM%22%5BAuthor%5D" class="usa-link"><span class="name western">Jean Marc Schiano de Collela</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Benizri%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Frédéric Benizri</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Frédéric Benizri</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Pharmacy Department, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Benizri%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Frédéric Benizri</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dutari%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Pilar Dutari</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Pilar Dutari</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dutari%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pilar Dutari</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Castoldi%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Cécile Castoldi</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Cécile Castoldi</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Castoldi%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cécile Castoldi</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Izadifar%E2%80%90Legrand%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Faezeh Izadifar‐Legrand</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Faezeh Izadifar‐Legrand</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Izadifar%E2%80%90Legrand%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Faezeh Izadifar‐Legrand</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Inchiappa%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Luca Inchiappa</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Luca Inchiappa</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Inchiappa%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luca Inchiappa</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Evans%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Catherine Evans</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Catherine Evans</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Evans%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Catherine Evans</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Brisou%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Gabriel Brisou</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Gabriel Brisou</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Brisou%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gabriel Brisou</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mescam%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Lenaig Mescam</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Lenaig Mescam</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Pathology, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mescam%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lenaig Mescam</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Camus%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Vincent Camus</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Vincent Camus</span></h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Department of Hematology, Centre Henri Becquerel, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Camus%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vincent Camus</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Reichert%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Thibaut Reichert</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Thibaut Reichert</span></h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>Department of Nuclear Medicine, Institut Paoli Calmettes, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Reichert%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Thibaut Reichert</span></a>
</div>
</div>
<sup>6</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="hon70060-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Hematology, Institut Paoli Calmettes, Marseille, France</div>
<div id="hon70060-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Clinical Research and Innovation – Biostatistics and Methodology Unit, Institut Paoli Calmettes, Marseille, France</div>
<div id="hon70060-aff-0003">
<sup>
<sup>3</sup>
</sup>Pharmacy Department, Institut Paoli Calmettes, Marseille, France</div>
<div id="hon70060-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Pathology, Institut Paoli Calmettes, Marseille, France</div>
<div id="hon70060-aff-0005">
<sup>
<sup>5</sup>
</sup>Department of Hematology, Centre Henri Becquerel, Rouen, France</div>
<div id="hon70060-aff-0006">
<sup>
<sup>6</sup>
</sup>Department of Nuclear Medicine, Institut Paoli Calmettes, Marseille, France</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong> Robin Noel, 
(<span>noelr@ipc.unicancer.fr</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Mar 5; Received 2024 Dec 27; Accepted 2025 Mar 14; Issue date 2025 May.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Hematological Oncology</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11993899  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40221881/" class="usa-link">40221881</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Immunochemotherapy has demonstrated high cure rates in primary mediastinal large B‐cell lymphoma (PMBCL). Recent findings from the IELSG 37 study show that certain specific dose‐dense treatment regimens are more likely to eliminate the need for consolidative radiation therapy, thereby reducing long‐term toxicity. Here, we report our experience with DA‐R‐EPOCH in a cohort of 70 patients treated at our cancer center. This retrospective, observational, single‐center study includes patients treated between 2013 and 2021. Treatment response was evaluated using positron emission tomography‐computed tomography (PET‐CT) scans and assessed according to the Deauville Score. With a median follow‐up of 36.4 months, 29% of patients achieved a complete metabolic response (CMR) on interim PET‐CT, while 71% achieved CMR at the end of treatment. Despite these results, 3‐year overall survival (OS) and progression‐free survival (PFS) rates were 99% and 93%, respectively. Our findings highlight the importance of tailoring treatment regimens, allowing for reduced reliance on consolidative therapies in line with recent advancements. Notably, none of the patients who achieved CMR on interim PET‐CT experienced relapse, and no disease progression was observed beyond 1 year after completing DA‐R‐EPOCH. Additionally, our results indicate that dose intensification beyond level 2 does not appear to improve survival, emphasizing the important implications for minimizing treatment‐related toxicity. We also analyzed the management and outcomes of refractory and relapsed cases, underscoring the challenges in treating non‐responding patients identified by interim PET‐CT, the limited efficacy of salvage immunochemotherapy, and the interesting role of radiation therapy in these cases.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> DA‐R‐EPOCH, PET‐CT, PMBCL, radiation therapy</p></section></section><section id="hon70060-sec-0010"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Mediastinal Large B‐cell Lymphoma (PMBCL) is a rare (&lt; 5%) subtype of B‐cell lymphoma [<a href="#hon70060-bib-0001" class="usa-link" aria-describedby="hon70060-bib-0001">1</a>, <a href="#hon70060-bib-0002" class="usa-link" aria-describedby="hon70060-bib-0002">2</a>]. Its pathological and clinical features, along with its gene expression signature and mutational landscape, overlap with those of nodular sclerosis classical Hodgkin lymphoma (NS‐cHL), distinguishing PMBCL from other aggressive lymphomas, particularly Diffuse Large B‐cell Lymphoma (DLBCL) [<a href="#hon70060-bib-0003" class="usa-link" aria-describedby="hon70060-bib-0003">3</a>, <a href="#hon70060-bib-0004" class="usa-link" aria-describedby="hon70060-bib-0004">4</a>].</p>
<p>Originating from medullary thymic B‐cells, the malignant cells in PMBCL express B‐cell markers but may lack surface immunoglobulin. Most PMBCL cases are CD30‐positive (with weak and partial staining, unlike cHL) and CD23‐positive. Transcriptional profiling has shown reduced expression of B‐cell receptor signaling in PMBCL. Molecular alterations involve key signaling pathways, including constitutive activation of NF‐κB and JAK‐STAT deregulation [<a href="#hon70060-bib-0005" class="usa-link" aria-describedby="hon70060-bib-0005">5</a>]. Amplification of the 9p24.1 region is common and leads to increased expression of programmed cell death protein 1 ligands (PD‐L1/CD274) and PD‐L2, providing a genetic mechanism for immune escape [<a href="#hon70060-bib-0006" class="usa-link" aria-describedby="hon70060-bib-0006">6</a>, <a href="#hon70060-bib-0007" class="usa-link" aria-describedby="hon70060-bib-0007">7</a>, <a href="#hon70060-bib-0008" class="usa-link" aria-describedby="hon70060-bib-0008">8</a>]. Additional genetic alterations contributing to immune escape include loss of major histocompatibility complex (MHC) class I and II, as well as structural variants in the MHC class II transactivator that reduce MHC class II expression [<a href="#hon70060-bib-0009" class="usa-link" aria-describedby="hon70060-bib-0009">9</a>, <a href="#hon70060-bib-0010" class="usa-link" aria-describedby="hon70060-bib-0010">10</a>, <a href="#hon70060-bib-0011" class="usa-link" aria-describedby="hon70060-bib-0011">11</a>, <a href="#hon70060-bib-0012" class="usa-link" aria-describedby="hon70060-bib-0012">12</a>].</p>
<p>PMBCL is typically characterized by the rapid development of an anterior mediastinal mass, often complicated by compressive syndrome, pleural, or pericardial effusions. Advanced‐stage disease is less common in PMBCL (ranging from 9.3% to 42.5% [<a href="#hon70060-bib-0013" class="usa-link" aria-describedby="hon70060-bib-0013">13</a>, <a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>, <a href="#hon70060-bib-0015" class="usa-link" aria-describedby="hon70060-bib-0015">15</a>, <a href="#hon70060-bib-0016" class="usa-link" aria-describedby="hon70060-bib-0016">16</a>, <a href="#hon70060-bib-0017" class="usa-link" aria-describedby="hon70060-bib-0017">17</a>]) compared to DLBCL. It most often occurs in young female patients during their third and fourth decades of life.</p>
<p>The optimal frontline treatment for PMBCL remains a subject of debate. Standard treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R‐CHOP21) with radiation therapy (RT) has been compared to more intensive regimens, such as Dose Adjusted Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin (DA‐R‐EPOCH) or R‐CHOP given every 2 weeks (R‐CHOP14). All of these regimens provide good disease control and prolonged overall survival. However, R‐CHOP21 without RT appears to yield inferior outcomes [<a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>, <a href="#hon70060-bib-0018" class="usa-link" aria-describedby="hon70060-bib-0018">18</a>, <a href="#hon70060-bib-0019" class="usa-link" aria-describedby="hon70060-bib-0019">19</a>]. More intensive regimens have shown the potential to eliminate the need for consolidative RT in patients with complete metabolic response, as demonstrated by recent results from the IELSG 37 study [<a href="#hon70060-bib-0020" class="usa-link" aria-describedby="hon70060-bib-0020">20</a>]; a finding that aligns with previous research [<a href="#hon70060-bib-0021" class="usa-link" aria-describedby="hon70060-bib-0021">21</a>]. This is significant as it reduces the long‐term toxicities associated with treatment, especially in the younger, predominantly female population affected by PMBCL [<a href="#hon70060-bib-0022" class="usa-link" aria-describedby="hon70060-bib-0022">22</a>, <a href="#hon70060-bib-0023" class="usa-link" aria-describedby="hon70060-bib-0023">23</a>]. Nevertheless, many patients, including those with a Deauville Score (DS) of four to five at the end of treatment (EoT), may still experience good disease control with frontline therapy [<a href="#hon70060-bib-0024" class="usa-link" aria-describedby="hon70060-bib-0024">24</a>, <a href="#hon70060-bib-0025" class="usa-link" aria-describedby="hon70060-bib-0025">25</a>].</p>
<p>A small subset of patients will be refractory or eventually relapse after frontline treatment, with a poor prognosis [<a href="#hon70060-bib-0026" class="usa-link" aria-describedby="hon70060-bib-0026">26</a>]. Few of these patients will achieve a complete metabolic response (CMR) after salvage immunochemotherapy prior to high‐dose chemotherapy and autologous stem cell transplantation (HDC/ASCT). Therefore, new therapeutic options, such as anti‐PD1 therapy, Brentuximab‐Vedotin, and Chimeric Antigen Receptor T‐cell (CAR‐T) therapy are of significant interest [<a href="#hon70060-bib-0027" class="usa-link" aria-describedby="hon70060-bib-0027">27</a>, <a href="#hon70060-bib-0028" class="usa-link" aria-describedby="hon70060-bib-0028">28</a>, <a href="#hon70060-bib-0029" class="usa-link" aria-describedby="hon70060-bib-0029">29</a>, <a href="#hon70060-bib-0030" class="usa-link" aria-describedby="hon70060-bib-0030">30</a>].</p>
<p>This manuscript presents our single‐center experience with the management of PMBCL, including patient characteristics, treatment approaches, response assessments, and long‐term outcomes. Additionally, we discuss the implications of these findings in the context of current clinical practice.</p></section><section id="hon70060-sec-0020"><h2 class="pmc_sec_title">2. Methods</h2>
<section id="hon70060-sec-0030"><h3 class="pmc_sec_title">2.1. Patients/Treatment</h3>
<p>The database of the Institut Paoli Calmettes (Marseille, France) was reviewed to identify all newly diagnosed PMBCL patients aged ≥ 18 years who were treated at the center following the introduction of DA‐R‐EPOCH as the recommended treatment in our local guidelines in 2013. Dose adjustments were made according to the protocol described by Dunleavy et al. [<a href="#hon70060-bib-0013" class="usa-link" aria-describedby="hon70060-bib-0013">13</a>].</p>
<p>Medical records were thoroughly reviewed to ensure that clinical and pathological features aligned with the World Health Organization (WHO) classifications' criteria [<a href="#hon70060-bib-0031" class="usa-link" aria-describedby="hon70060-bib-0031">31</a>, <a href="#hon70060-bib-0032" class="usa-link" aria-describedby="hon70060-bib-0032">32</a>, <a href="#hon70060-bib-0033" class="usa-link" aria-describedby="hon70060-bib-0033">33</a>]. 18F‐FDG PET‐CT data were analyzed by one nuclear medicine physician (TR) using Siemens SyngoVia software. Metabolic Tumor Volume (MTV) was calculated using a supervised segmentation of the tumor regions, applying a 41% SUVmax threshold to automatically detected hypermetabolic areas [<a href="#hon70060-bib-0034" class="usa-link" aria-describedby="hon70060-bib-0034">34</a>]. The Total Metabolic Tumor Volume (TMTV) was defined as the combined metabolic volume across all individual lesions.</p></section><section id="hon70060-sec-0040"><h3 class="pmc_sec_title">2.2. Response Assessment</h3>
<p>All patients were assessed by an interim (iPET‐CT) and an end of treatment (ePET‐CT) 18F‐FDG PET‐CT according to the Lugano criteria [<a href="#hon70060-bib-0035" class="usa-link" aria-describedby="hon70060-bib-0035">35</a>].</p></section><section id="hon70060-sec-0050"><h3 class="pmc_sec_title">2.3. Statistical Analysis</h3>
<p>Survival probabilities were assessed from the start of treatment until the occurrence of the event of interest. For overall survival (OS), the event was death from any cause, and for progression‐free survival (PFS), the events included progression, relapse, second lymphoma treatment, or death. Patients who did not experience any event were censored at the date of their last contact. OS and PFS probabilities were calculated using the Kaplan‐Meier method, and univariate associations were evaluated using the log‐rank test. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA), with a nominal level of statistical significance (two‐tailed) set at 0.05.</p></section></section><section id="hon70060-sec-0060"><h2 class="pmc_sec_title">3. Results</h2>
<p>We retrospectively collected the data from 74 patients with a diagnosis of PMBCL treated at our center between January 2013 and December 2021, (see Figure <a href="#hon70060-fig-0001" class="usa-link">1</a>; 4 patients excluded from analysis).</p>
<figure class="fig xbox font-sm" id="hon70060-fig-0001"><h3 class="obj_head">FIGURE 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221f/11993899/b1efa73c82f4/HON-43-e70060-g003.jpg" loading="lazy" id="jats-graphic-1" height="614" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/hon70060-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart. cHL, Classical Hodgkin Lymphoma; PMBCL, Primary Mediastinal B Cell Lymphoma.</p></figcaption></figure><section id="hon70060-sec-0070"><h3 class="pmc_sec_title">3.1. Patient Characteristics</h3>
<p>The median follow‐up for these patients was 36.4 months (95% CI: [30.2–45.3]). The median age at diagnosis was 34.4 years, with 68% of patients being female. B symptoms were present in 40.3% of patients, while 79.2% had localized disease. Bulky disease was common, with 61.4% of patients presenting with a mass larger than 10 cm. Local extranodal involvement was observed in 23.6% of patients. Low International Prognostic Index (IPI) was observed in 72.9% of patients (see Table <a href="#hon70060-tbl-0001" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="hon70060-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Patients' characteristics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Cohort = 72 patients</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Missing data</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Median age (yr) [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">34.4 [18.4–70.7]</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Female sex—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">49 (68%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">B symptoms—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">29 (40.3%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">ECOG status</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 [0–4]</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&lt; 2—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">61 (84.7%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥ 2—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">11 (15.3%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">Stage</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 [1—4]</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I/II—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">57 (79.2%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III/IV—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (20.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Local extranodal involvement—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">17 (23.6%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt; 1 extra nodal involvement—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (7%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Organ involvement—<em>n</em>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">32 (45%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Lung</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (21.1%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Intestines</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Thoracic wall</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (4.2%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Bone</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (5.6%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pleura</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Kidney</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.4%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pericardium</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Stomach</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pancreas</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Thyroid</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.4%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Adrenal glands</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.8%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bulky tumor ≥ 7 cm—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">52 (74.3%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bulky tumor ≥ 10 cm—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">43 (61.4%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Baseline total metabolic tumor volume (TMTV)—median [min–max] cm<sup>3</sup>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">173 [1.8–1233]</td>
<td align="center" valign="top" rowspan="1" colspan="1">13</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pleural effusion—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">27 (37.5%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pericardial effusion—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">22 (30.6%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Superior Vena Cava Syndrome—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">32 (44.4%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">Biologic parameters</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Elevated LDH—<em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">56 (80)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median (UI/L) [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">331 [130–1310]</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hemoglobin (g/L) [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">125 [69–151]</td>
<td align="center" valign="top" rowspan="1" colspan="1">7</td>
</tr>
<tr><td colspan="3" align="left" valign="top" rowspan="1">Prognostic scores</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IPI—median [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 [0–4]</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≤ 1—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">51 (72.9%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">&gt; 1—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">19 (27.1%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NCCN‐IPI—median [range]</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 [0–5]</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≤ 2—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">53 (75.7%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">&gt; 2—number</td>
<td align="center" valign="top" rowspan="1" colspan="1">17 (24.3%)</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/hon70060-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="hon70060-sec-0080"><h3 class="pmc_sec_title">3.2. Treatment Characteristics (see Supporting Information <a href="#hon70060-sup-0001" class="usa-link">S1</a>)</h3>
<p>Seventy patients (97.2%) received DA‐R‐EPOCH, with only 2 patients receiving an R‐CHOP21‐like treatment due to poor ECOG performance status. Debulking chemotherapy (cyclophosphamide, vincristine, prednisone—COP) was administered at the discretion of the treating physician to 21 patients (29.2%) prior to initiating frontline immunochemotherapy. Five patients (6.9%) received RT at the EoT—four for partial response at iPET‐CT and one for partial response at ePET‐CT. Additionally, five patients (6.9%) underwent consolidative HDC/ASCT. All consolidative therapies were performed between 2013 and 2016, with none administered thereafter.</p></section><section id="hon70060-sec-0090"><h3 class="pmc_sec_title">3.3. Clinical Outcome</h3>
<p>The median follow‐up was 36.4 months (95% CI: 30.16–45.31). With only one death, related to lymphoma, the 3‐year OS rate was 99% (95% CI: 0.90–1) (see Figure <a href="#hon70060-fig-0002" class="usa-link">2</a>). After censoring patients with consolidative treatment, the results were found to be similar for those patients (98% (95% CI: 0.89–1)) (see Supporting Information <a href="#hon70060-sup-0001" class="usa-link">S1</a>).</p>
<figure class="fig xbox font-sm" id="hon70060-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221f/11993899/418e8d5739b4/HON-43-e70060-g004.jpg" loading="lazy" id="jats-graphic-3" height="1196" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/hon70060-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Overall Survival (OS) (A) and progression free survival (PFS) (B) for the whole Cohort treated with DA‐R‐EPOCH (70 patients).</p></figcaption></figure><p>Three patients experienced progression during treatment, and two relapsed after completing treatment. The 3‐year PFS rate was 93% (95% CI: 0.83–0.97) (93% [95% CI: 0.83–0.97] after censoring). Four out of the five patients who relapsed underwent a new biopsy to confirm the relapse. Two patients initially diagnosed and treated as PMBCL with DA‐R‐EPOCH were later reclassified as having Mediastinal Gray Zone Lymphoma (MGZL) with cHL features upon biopsy at relapse and were therefore excluded from this analysis.</p>
<p>An iPET‐CT was performed for all patients, with 44.3% undergoing it after 2 cycles and 1.4% after 4 cycles prior to 2018. After 2018, 54.3% of patients underwent iPET‐CT after 3 cycles, in accordance with our updated guidelines. Patients with a DS of 5 on iPET‐CT had significantly shorter PFS (<em>p</em> = 0.001; HR = 0.63 [95% CI: 0.23–0.86]) in univariate analysis. The same trend was observed for DS 5 on ePET‐CT, as shown in Figure <a href="#hon70060-fig-0003" class="usa-link">3</a> (<em>p</em> &lt; 0.001; HR = 0.60 [95% CI: 0.13–0.88]).</p>
<figure class="fig xbox font-sm" id="hon70060-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221f/11993899/344ddc82a0eb/HON-43-e70060-g001.jpg" loading="lazy" id="jats-graphic-5" height="1115" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/hon70060-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Progression‐free survival (PFS) stratified by Deauville Score on (A) interim PET‐CT (iPET‐CT) and (B) end‐of‐treatment PET‐CT (ePET‐CT) of patients treated with DA‐R‐EPOCH.</p></figcaption></figure><p>Univariate analysis of other baseline characteristics (see Supporting Information <a href="#hon70060-sup-0001" class="usa-link">S1</a>) revealed no significant impact on outcomes, except for the presence of pericardial effusion. The maximum dose level (≤ 2 or &gt; 2) did not significantly influence outcomes (<em>p</em> = 0.125), nor did the IPI (≤ 1 or &gt; 1) or NCCN‐IPI (≤ 2 or &gt; 2), consistent with previous observations [<a href="#hon70060-bib-0019" class="usa-link" aria-describedby="hon70060-bib-0019">19</a>]. Due to the low number of events, multivariate analysis and a meaningful analysis of OS could not be performed.</p></section><section id="hon70060-sec-0100"><h3 class="pmc_sec_title">3.4. Treatment Related Toxicity (see Supporting Information <a href="#hon70060-sup-0001" class="usa-link">S1</a>)</h3>
<p>Dose level adjustments were made according to the protocol outlined by Dunleavy et al. [<a href="#hon70060-bib-0013" class="usa-link" aria-describedby="hon70060-bib-0013">13</a>].</p>
<p>All patients received prophylactic medications, including Cotrimoxazole, Valaciclovir, and Granulocyte Colony‐Stimulating Factor. Blood counts were monitored once weekly. None of the 43 patients, for whom data was available, developed tumor lysis syndrome (TLS).</p>
<p>Hematological toxicity was the most common side effect, as defined by the Common Terminology Criteria for Adverse Events, Version 5.0. Grade 4 neutropenia was the most frequent adverse event and the primary reason for not increasing the dose level, while grade 4 thrombocytopenia was rare.</p>
<p>Dose levels were never reduced due to grade 4 hematological toxicity. Only two patients required a dose reduction due to grade 3 mucositis, which necessitated prolonged hospitalization. Febrile neutropenia of grade ≥ 2 occurred in 29 out of 70 patients, while infectious complications of grade ≥ 2 were observed in 24 patients. No treatment‐related deaths occurred.</p></section><section id="hon70060-sec-0110"><h3 class="pmc_sec_title">3.5. Outcome of Refractory/Relapsed (R/R) Patients</h3>
<p>The median time from treatment onset to relapse or progression was 6.11 months (95% CI: [3.75–16.53]), with no relapses occurring beyond 12 months after the completion of treatment.</p>
<p>The first refractory patient initially had stage IAX disease and showed progression on ePET‐CT after achieving only DS 5 with PMR on iPET‐CT. A biopsy confirmed the progression. The patient received two salvage regimens—Rituximab‐Dexamethasone High‐dose Cytarabine (R‐DHAC) and Rituximab‐Ifosfamide Etoposide Cytarabine Methotrexate (R‐IVAM), but did not respond. He was subsequently referred for RT targeting the mediastinal mass (50 Gy) as a bridging treatment for Axi‐Cel, achieving good local control. Unfortunately, progression occurred at other sites before CAR T‐cells reinfusion in April 2020. After reinfusion, the patient experienced a slow but steady response and achieved an ongoing CMR after 7 months.</p>
<p>The second refractory patient had stage IIBX disease at diagnosis. The patient had progressive stage IA disease on ePET‐CT after achieving a DS 5 PMR on iPET‐CT. She subsequently received RT (28 Gy) and achieved DS 4 PMR at the EoT, remaining relapse‐free 20 months later.</p>
<p>The third refractory patient also had stage IIBX disease. She only achieved DS 5 stable disease on iPET‐CT. A new biopsy confirmed the diagnosis. Due to the high MTV, she was not eligible for RT. She then received four different treatments (R‐DHAC, Ifosfamide Carboplatin Etoposide [ICE], IVAM, Brentuximab‐Vedotin‐Doxorubicin Vinblastine Dacarbazine [BV‐AVD]), but eventually died from disease progression.</p>
<p>The first relapsed patient had stage IIAX (CNS‐IPI 1) disease and received consolidative RT due to a DS 4 PMR on both iPET‐CT and ePET‐CT. She experienced an isolated central nervous system (CNS) relapse, confirmed by biopsy, 4 months after the EoT. She then underwent high‐dose salvage treatment (Cyclophosphamide, Vincristine, Prednisone, Folinic Acid, Doxorubicin, Methotrexate/COPADM), which was unsuccessful. She was subsequently referred for palliative whole‐brain RT (dose unknown) and remained relapse‐free for 78 months.</p>
<p>The second relapsed patient had stage IIBX disease. She achieved a DS 4 PMR on iPET‐CT and a DS 3 CMR on ePET‐CT. Ten months later, she relapsed with stage IA mediastinal disease, confirmed by biopsy. She failed salvage therapy (R‐ICE) with local progression and received local RT, achieving CR before undergoing Axi‐Cel therapy in May 2021. She has remained relapse‐free since.</p></section></section><section id="hon70060-sec-0120"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>Our results confirm the efficacy and safety of DA‐R‐EPOCH as a frontline treatment for patients with PMBCL, with a 3‐year PFS of 93% and a 3‐year OS of 99%, consistent with previous studies [<a href="#hon70060-bib-0013" class="usa-link" aria-describedby="hon70060-bib-0013">13</a>, <a href="#hon70060-bib-0015" class="usa-link" aria-describedby="hon70060-bib-0015">15</a>, <a href="#hon70060-bib-0036" class="usa-link" aria-describedby="hon70060-bib-0036">36</a>, <a href="#hon70060-bib-0037" class="usa-link" aria-describedby="hon70060-bib-0037">37</a>, <a href="#hon70060-bib-0038" class="usa-link" aria-describedby="hon70060-bib-0038">38</a>, <a href="#hon70060-bib-0039" class="usa-link" aria-describedby="hon70060-bib-0039">39</a>, <a href="#hon70060-bib-0040" class="usa-link" aria-describedby="hon70060-bib-0040">40</a>] (see Supporting Information <a href="#hon70060-sup-0001" class="usa-link">S1</a>). The main toxicities observed were in line with those reported in the literature [<a href="#hon70060-bib-0013" class="usa-link" aria-describedby="hon70060-bib-0013">13</a>, <a href="#hon70060-bib-0036" class="usa-link" aria-describedby="hon70060-bib-0036">36</a>, <a href="#hon70060-bib-0037" class="usa-link" aria-describedby="hon70060-bib-0037">37</a>, <a href="#hon70060-bib-0041" class="usa-link" aria-describedby="hon70060-bib-0041">41</a>, <a href="#hon70060-bib-0042" class="usa-link" aria-describedby="hon70060-bib-0042">42</a>]. Notably, no patients in our cohort developed TLS, and therefore, we do not routinely prevent nor monitor it. CNS relapse was rare (1 in 5), in line with previous studies, ranging from 2.9% to 37% [<a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>, <a href="#hon70060-bib-0015" class="usa-link" aria-describedby="hon70060-bib-0015">15</a>, <a href="#hon70060-bib-0038" class="usa-link" aria-describedby="hon70060-bib-0038">38</a>, <a href="#hon70060-bib-0040" class="usa-link" aria-describedby="hon70060-bib-0040">40</a>].</p>
<p>No study has directly compared different intensive regimens, making it challenging to speculate on the superiority of one over another. Any comparison should also account for the associated toxicity. The IELSG37 trial prospectively evaluated the role of RT in patients achieving CMR after chemoimmunotherapy. The trial found no significant difference between the RT and observation groups, but it was not designed to assess the impact of different chemoimmunotherapies [<a href="#hon70060-bib-0020" class="usa-link" aria-describedby="hon70060-bib-0020">20</a>]. Nonetheless, the study highlighted the importance of intensive regimens compared to R‐CHOP21, in achieving EoT CMR [<a href="#hon70060-bib-0018" class="usa-link" aria-describedby="hon70060-bib-0018">18</a>, <a href="#hon70060-bib-0020" class="usa-link" aria-describedby="hon70060-bib-0020">20</a>], thereby reducing the need for RT. In the IELSG37 trial, patients treated with R‐CHOP21 had a higher risk of a DS of 5 (25%), whereas regimens like DA‐R‐EPOCH had a DS 5 rate of less than 10%. In our cohort, 7.3% of patients had a DS 5 (see Figure <a href="#hon70060-fig-0004" class="usa-link">4</a>). Other studies have similarly demonstrated the benefits of more intensive regimens for better disease control [<a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>, <a href="#hon70060-bib-0019" class="usa-link" aria-describedby="hon70060-bib-0019">19</a>, <a href="#hon70060-bib-0037" class="usa-link" aria-describedby="hon70060-bib-0037">37</a>]. The LYSA group reported retrospective outcomes from both clinical trials [<a href="#hon70060-bib-0019" class="usa-link" aria-describedby="hon70060-bib-0019">19</a>] and real‐world settings [<a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>]. The R‐ACVBP and R‐CHOP14 regimens showed superior PFS and OS when compared to R‐CHOP21. The R‐CHOP14 regimen in these studies showed promising results, with a 3‐year PFS of 89.4% and 3‐year OS of 100% [<a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>], and a 4‐year PFS of 78% and 4‐year OS of 89% [<a href="#hon70060-bib-0019" class="usa-link" aria-describedby="hon70060-bib-0019">19</a>]. However, 31.6% and 14.5% of these patients received consolidative HDC/ASCT or RT. In contrast, only 6.9% of our cohort received consolidative HDC/ASCT, and 6.9% received RT. This reflects the refinement of our treatment guidelines after 2017, incorporating PET‐CT assessments without compromising outcomes. Consequently, it is difficult to conclude that R‐CHOP14 is non‐inferior to other intensive regimens.</p>
<figure class="fig xbox font-sm" id="hon70060-fig-0004"><h3 class="obj_head">FIGURE 4.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221f/11993899/fb5165cb27e0/HON-43-e70060-g002.jpg" loading="lazy" id="jats-graphic-7" height="405" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/hon70060-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Interim and end of treatment (EOT) PET‐CT response according to the Deauville Score (70 patients treated with DA‐R‐EPOCH). iPET‐CT, Interim positron emission tomography—computed tomography (PET‐CT); ePET‐CT, end of treatment PET CT.</p></figcaption></figure><p>In our cohort, there was no significant difference in outcomes between patients who received a higher dose of treatment (dose level ≤ or &gt; 2; <em>p</em> = 0.125). A similar report [<a href="#hon70060-bib-0015" class="usa-link" aria-describedby="hon70060-bib-0015">15</a>] showed comparable results with dose levels ≤ or &gt; 3. These findings are notable because they suggest that dose escalation can be mitigated to reduce toxicity while maintaining efficacy. Of particular interest, none of the patients (29%) who achieved a CMR on the iPET‐CT relapsed, demonstrating an excellent negative predictive value (100% for iPET‐CT and 98% for ePET‐CT), consistent with other studies [<a href="#hon70060-bib-0024" class="usa-link" aria-describedby="hon70060-bib-0024">24</a>, <a href="#hon70060-bib-0039" class="usa-link" aria-describedby="hon70060-bib-0039">39</a>]. This observation allows for safely omitting ePET‐CT in patients with a CMR and potentially avoiding unnecessary treatments and escalating doses in this subgroup.</p>
<p>In contrast, all patients with R/R disease had a positive iPET‐CT according to the Deauville Score. A DS of 5 at the end of treatment was associated with a higher risk of relapse, but this also highlights the poor positive predictive value of a DS of 4 or 5, as only 6.7% of patients with DS 4% and 40% with DS 5 experienced relapse or progression [<a href="#hon70060-bib-0015" class="usa-link" aria-describedby="hon70060-bib-0015">15</a>, <a href="#hon70060-bib-0025" class="usa-link" aria-describedby="hon70060-bib-0025">25</a>]. This underscores the need for a new core or excisional biopsy before initiating second‐line treatments, whenever possible, to rule out residual inflammation and/or fibrosis [<a href="#hon70060-bib-0024" class="usa-link" aria-describedby="hon70060-bib-0024">24</a>, <a href="#hon70060-bib-0043" class="usa-link" aria-describedby="hon70060-bib-0043">43</a>]. In our experience, larger resections are preferable since smaller biopsies often yield necrotic tissue or inflammation, which can be misleadingly reassuring. Systematic biopsies also help refine the diagnosis. Two patients were found to have MGZL with cHL features at relapse.</p>
<p>If an excisional biopsy is not feasible, we suggest two approaches. For patients with a DS of 4, “watch and wait” or serial PET‐CT scan at 3‐month are reasonable options. For patients with a DS of 5, consolidative RT to the residual lesion should be considered to avoid the need for more aggressive salvage treatments. Among other baseline parameters, only the presence of pericardial effusion was associated with worse PFS in univariate analysis, a finding also reported in other studies [<a href="#hon70060-bib-0014" class="usa-link" aria-describedby="hon70060-bib-0014">14</a>, <a href="#hon70060-bib-0044" class="usa-link" aria-describedby="hon70060-bib-0044">44</a>].</p>
<p>Another noteworthy practical finding is that none of the R/R patients relapsed beyond 1 year after completing treatment, consistent with other observations [<a href="#hon70060-bib-0039" class="usa-link" aria-describedby="hon70060-bib-0039">39</a>].</p>
<p>Finally, our experience in managing R/R patients highlights the interesting role of RT whenever feasible, as emphasized by others [<a href="#hon70060-bib-0015" class="usa-link" aria-describedby="hon70060-bib-0015">15</a>, <a href="#hon70060-bib-0045" class="usa-link" aria-describedby="hon70060-bib-0045">45</a>]. Indeed, among the four patients who received RT, two were cured, and one achieved a CMR before undergoing CAR T‐cell therapy. Currently, there is no standard treatment for patients ineligible for RT. Our data also underscores the poor efficacy of immunochemotherapy in the salvage setting, with no response observed in the four patients who received it, consistent with findings from another group [<a href="#hon70060-bib-0026" class="usa-link" aria-describedby="hon70060-bib-0026">26</a>]. One study reported interesting outcomes, but 57% of the patients had not received Rituximab as part of their frontline treatment, and 87% had also received RT prior to HDC/ASCT [<a href="#hon70060-bib-0046" class="usa-link" aria-describedby="hon70060-bib-0046">46</a>]. While HDC/ASCT can be highly effective [<a href="#hon70060-bib-0045" class="usa-link" aria-describedby="hon70060-bib-0045">45</a>], achieving a metabolic response beforehand remains a challenge. Two trials [<a href="#hon70060-bib-0027" class="usa-link" aria-describedby="hon70060-bib-0027">27</a>, <a href="#hon70060-bib-0028" class="usa-link" aria-describedby="hon70060-bib-0028">28</a>] have demonstrated the potential of anti‐PD‐1 monoclonal antibodies, with overall response rates ranging from 48% in monotherapy to 73.3% when combined with anti‐CD30 antibody‐drug conjugates (Brentuximab‐Vedotin). Some reports also suggest that this combination could be useful as a bridging therapy [<a href="#hon70060-bib-0047" class="usa-link" aria-describedby="hon70060-bib-0047">47</a>]. The use of CAR‐T in R/R PMBCL shows promise, but clinical trial data remains limited and mostly comes from retrospective series [<a href="#hon70060-bib-0029" class="usa-link" aria-describedby="hon70060-bib-0029">29</a>, <a href="#hon70060-bib-0030" class="usa-link" aria-describedby="hon70060-bib-0030">30</a>, <a href="#hon70060-bib-0048" class="usa-link" aria-describedby="hon70060-bib-0048">48</a>]. Currently, there is no consensus on the optimal consolidative strategy following response induction. Based on our experience, the salvage approach for advanced disease, when RT is not feasible, involves combining Brentuximab Vedotin and Nivolumab before proceeding to consolidative treatments, including RT, CAR T‐cell therapy, or HDC/ASCT.</p></section><section id="hon70060-sec-0130"><h2 class="pmc_sec_title">5. Conclusion</h2>
<p>Despite the retrospective nature of our study and its inherent limitations, DA‐R‐EPOCH remains a safe and effective treatment for newly diagnosed PMBCL, curing most patients without the need for consolidative RT. Our data indicate no survival difference between patients treated with dose levels ≤ 2 or &gt; 2. Therefore, dose escalation may not be necessary for patients achieving CMR in iPET‐CT. Additionally, in patients achieving CMR with a DS of 1–3, the ePET‐CT can be safely omitted. Furthermore, our findings highlight the importance of performing an excisional biopsy to confirm relapse and rule out differential diagnoses such as MGZL before initiating second‐line treatment. Finally, our study emphasizes the interesting role of RT in managing R/R patients. However, there is a need for more accurate tools to better discriminate between patients with a DS of 4–5. As such, our future work will focus on identifying improved PET‐CT metrics for PET‐positive patients.</p></section><section id="hon70060-sec-0140"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>
<strong>Robin Noel:</strong> conceptualization, methodology, data curation, data analysis, writing – original draft, patients' care. <strong>Catalina Montes de Oca:</strong> conceptualization, methodology, data curation, data analysis, writing – review and editing, patients' care. <strong>Patrick Sfumato:</strong> methodology, statistical analysis, writing – review and editing. <strong>Anne Calleja:</strong> data curation, data analysis, patients' care. <strong>Aude Collignon:</strong> patients' care. <strong>Ferdinand Villetard:</strong> patients' care. <strong>Jean Marc Schiano de Collela:</strong> patients' care. <strong>Frédéric Benizri:</strong> patients' care. <strong>Pilar Dutari:</strong> patients' care. <strong>Cécile Castoldi:</strong> patients' care. <strong>Faezeh Izadifar‐Legrand:</strong> patients' care. <strong>Luca Inchiappa:</strong> patients' care. <strong>Catherine Evans:</strong> patients' care. <strong>Gabriel Brisou:</strong> patients' care. <strong>Lenaig Mescam:</strong> writing – review and editing. <strong>Vincent Camus:</strong> data curation, data analysis, writing – review and editing. <strong>Thibaut Reichert:</strong> conceptualization, data curation, data analysis, writing – review and editing.</p></section><section id="hon70060-sec-0160"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>The study was approved by the Institutional Review Board at Institut Paoli Calmettes, Marseille, France, in May 2022 and was compliant with institutional guidelines and the Declaration of Helsinki.</p></section><section id="hon70060-sec-0170"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="hon70060-sec-0190"><h3 class="pmc_sec_title">Peer Review</h3>
<p>The peer review history for this article is available at <a href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70060</a>.</p></section><section id="sec19"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="hon70060-sup-0001"><div class="caption p"><p>Supporting Information S1</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11993899/bin/HON-43-e70060-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70060-s001.docx</a><sup> (121.5KB, docx) </sup>
</div></div></section></section><section id="hon70060-sec-0150" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Joanna Lotocka who reviewed and edited English language.</p></section><section id="notes1"><section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="hon70060-note-0001"><p>
<strong>Funding:</strong> The authors received no specific funding for this work.</p></div></div></section></section><section id="hon70060-sec-0200"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></section><section id="hon70060-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="hon70060-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="hon70060-bib-0001">
<span class="label">1.</span><cite>
Bhatt V. R., Mourya R., Shrestha R., and Armitage J. O., “Primary Mediastinal Large B‐Cell Lymphoma,” Cancer Treatment Reviews
41, no. 6 (June 2015): 476–485, 10.1016/j.ctrv.2015.04.006.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2015.04.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25913715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treatment%20Reviews&amp;title=Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=V.%20R.%20Bhatt&amp;author=R.%20Mourya&amp;author=R.%20Shrestha&amp;author=J.%20O.%20Armitage&amp;volume=41&amp;issue=6&amp;publication_year=June%202015&amp;pages=476-485&amp;pmid=25913715&amp;doi=10.1016/j.ctrv.2015.04.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0002">
<span class="label">2.</span><cite>
Vitolo U., Seymour J., Martelli M., et al., “Extranodal Diffuse Large B‐Cell Lymphoma (DLBCL) and Primary Mediastinal B‐Cell Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up,” Annals of Oncology, the Journal of the European Society for Medical Oncology
27, no. suppl 5 (september 2016): v91–v102, 10.1093/annonc/mdw175.</cite> [<a href="https://doi.org/10.1093/annonc/mdw175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27377716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology,%20the%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology&amp;title=Extranodal%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20(DLBCL)%20and%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma:%20ESMO%20Clinical%20Practice%20Guidelines%20for%20Diagnosis,%20Treatment%20and%20Follow%E2%80%90Up&amp;author=U.%20Vitolo&amp;author=J.%20Seymour&amp;author=M.%20Martelli&amp;volume=27&amp;issue=suppl%205&amp;publication_year=september%202016&amp;pages=v91-v102&amp;pmid=27377716&amp;doi=10.1093/annonc/mdw175&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0003">
<span class="label">3.</span><cite>
Rosenwald A., Wright G., Leroy K., et al., “Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma,” Journal of Experimental Medicine
198, no. 6 (september 2003): 851–862, 10.1084/jem.20031074.
</cite> [<a href="https://doi.org/10.1084/jem.20031074" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2194208/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12975453/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Experimental%20Medicine&amp;title=Molecular%20Diagnosis%20of%20Primary%20Mediastinal%20B%20Cell%20Lymphoma%20Identifies%20a%20Clinically%20Favorable%20Subgroup%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma%20Related%20to%20Hodgkin%20Lymphoma&amp;author=A.%20Rosenwald&amp;author=G.%20Wright&amp;author=K.%20Leroy&amp;volume=198&amp;issue=6&amp;publication_year=september%202003&amp;pages=851-862&amp;pmid=12975453&amp;doi=10.1084/jem.20031074&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0004">
<span class="label">4.</span><cite>
Alaggio R., Amador C., Anagnostopoulos I., et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms,” Leukemia
36, no. 7 (juill 2022): 1720–1748, 10.1038/s41375-022-01620-2.
</cite> [<a href="https://doi.org/10.1038/s41375-022-01620-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9214472/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35732829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=The%205th%20Edition%20of%20the%20World%20Health%20Organization%20Classification%20of%20Haematolymphoid%20Tumours:%20Lymphoid%20Neoplasms&amp;author=R.%20Alaggio&amp;author=C.%20Amador&amp;author=I.%20Anagnostopoulos&amp;volume=36&amp;issue=7&amp;publication_year=juill%202022&amp;pages=1720-1748&amp;pmid=35732829&amp;doi=10.1038/s41375-022-01620-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0005">
<span class="label">5.</span><cite>
Twa D. D. W., Chan F. C., Ben‐Neriah S., et al., “Genomic Rearrangements Involving Programmed Death Ligands Are Recurrent in Primary Mediastinal Large B‐Cell Lymphoma,” Blood
123, no. 13 (mars 2014): 2062–2065, 10.1182/blood-2013-10-535443.
</cite> [<a href="https://doi.org/10.1182/blood-2013-10-535443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24497532/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Genomic%20Rearrangements%20Involving%20Programmed%20Death%20Ligands%20Are%20Recurrent%20in%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=D.%20D.%20W.%20Twa&amp;author=F.%20C.%20Chan&amp;author=S.%20Ben%E2%80%90Neriah&amp;volume=123&amp;issue=13&amp;publication_year=mars%202014&amp;pages=2062-2065&amp;pmid=24497532&amp;doi=10.1182/blood-2013-10-535443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0006">
<span class="label">6.</span><cite>
Green M. R., Monti S., Rodig S. J., et al., “Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD‐1 Ligand Expression, and Further Induction Via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B‐Cell Lymphoma,” Blood
116, no. 17 (october 2010): 3268–3277, 10.1182/blood-2010-05-282780.
</cite> [<a href="https://doi.org/10.1182/blood-2010-05-282780" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2995356/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20628145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Integrative%20Analysis%20Reveals%20Selective%209p24.1%20Amplification,%20Increased%20PD%E2%80%901%20Ligand%20Expression,%20and%20Further%20Induction%20Via%20JAK2%20in%20Nodular%20Sclerosing%20Hodgkin%20Lymphoma%20and%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=M.%20R.%20Green&amp;author=S.%20Monti&amp;author=S.%20J.%20Rodig&amp;volume=116&amp;issue=17&amp;publication_year=october%202010&amp;pages=3268-3277&amp;pmid=20628145&amp;doi=10.1182/blood-2010-05-282780&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0007">
<span class="label">7.</span><cite>
Chapuy B., Stewart C., Dunford A. J., et al., “Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD‐1 Blockade,” Blood
134, no. 26 (2019): 2369–2382, 10.1182/blood.2019002067.
</cite> [<a href="https://doi.org/10.1182/blood.2019002067" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6933293/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31697821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Genomic%20Analyses%20of%20PMBL%20Reveal%20New%20Drivers%20and%20Mechanisms%20of%20Sensitivity%20to%20PD%E2%80%901%20Blockade&amp;author=B.%20Chapuy&amp;author=C.%20Stewart&amp;author=A.%20J.%20Dunford&amp;volume=134&amp;issue=26&amp;publication_year=2019&amp;pages=2369-2382&amp;pmid=31697821&amp;doi=10.1182/blood.2019002067&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0008">
<span class="label">8.</span><cite>
Wienand K., Chapuy B., Stewart C., et al., “Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD‐1 Blockade,” Blood
134, no. Supplement_1 (november 2019): 1493, 10.1182/blood-2019-131904.</cite> [<a href="https://doi.org/10.1182/blood-2019-131904" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6933293/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31697821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Comparative%20Genomic%20Analyses%20Defines%20Shared%20and%20Unique%20Features%20of%20cHL%20and%20PMBL%20and%20New%20Mechanisms%20of%20Sensitivity%20to%20PD%E2%80%901%20Blockade&amp;author=K.%20Wienand&amp;author=B.%20Chapuy&amp;author=C.%20Stewart&amp;volume=134&amp;issue=Supplement_1&amp;publication_year=november%202019&amp;pages=1493&amp;pmid=31697821&amp;doi=10.1182/blood-2019-131904&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0009">
<span class="label">9.</span><cite>
Mottok A., Woolcock B., Chan F. C., et al., “Genomic Alterations in CIITA are Frequent in Primary Mediastinal Large B Cell Lymphoma and are Associated With Diminished MHC Class II Expression,” Cell Reports
13, no. 7 (november 2015): 1418–1431, 10.1016/j.celrep.2015.10.008.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2015.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26549456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Reports&amp;title=Genomic%20Alterations%20in%20CIITA%20are%20Frequent%20in%20Primary%20Mediastinal%20Large%20B%20Cell%20Lymphoma%20and%20are%20Associated%20With%20Diminished%20MHC%20Class%20II%20Expression&amp;author=A.%20Mottok&amp;author=B.%20Woolcock&amp;author=F.%20C.%20Chan&amp;volume=13&amp;issue=7&amp;publication_year=november%202015&amp;pages=1418-1431&amp;pmid=26549456&amp;doi=10.1016/j.celrep.2015.10.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0010">
<span class="label">10.</span><cite>
Steidl C., Shah S. P., Woolcock B. W., et al., “MHC Class II Transactivator CIITA is a Recurrent Gene Fusion Partner in Lymphoid Cancers,” Nature
471, no. 7338 (mars 2011): 377–381, 10.1038/nature09754.
</cite> [<a href="https://doi.org/10.1038/nature09754" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3902849/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21368758/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=MHC%20Class%20II%20Transactivator%20CIITA%20is%20a%20Recurrent%20Gene%20Fusion%20Partner%20in%20Lymphoid%20Cancers&amp;author=C.%20Steidl&amp;author=S.%20P.%20Shah&amp;author=B.%20W.%20Woolcock&amp;volume=471&amp;issue=7338&amp;publication_year=mars%202011&amp;pages=377-381&amp;pmid=21368758&amp;doi=10.1038/nature09754&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0011">
<span class="label">11.</span><cite>
Roberts R. A., “Loss of Major Histocompatibility Class II Gene and Protein Expression in Primary Mediastinal Large B‐Cell Lymphoma is Highly Coordinated and Related to Poor Patient Survival,” Blood
108, no. 1 (juill 2006): 311–318, 10.1182/blood-2005-11-4742.
</cite> [<a href="https://doi.org/10.1182/blood-2005-11-4742" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1895840/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16543468/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Loss%20of%20Major%20Histocompatibility%20Class%20II%20Gene%20and%20Protein%20Expression%20in%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma%20is%20Highly%20Coordinated%20and%20Related%20to%20Poor%20Patient%20Survival&amp;author=R.%20A.%20Roberts&amp;volume=108&amp;issue=1&amp;publication_year=juill%202006&amp;pages=311-318&amp;pmid=16543468&amp;doi=10.1182/blood-2005-11-4742&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0012">
<span class="label">12.</span><cite>
Lenz G., Wright G. W., Emre N. C. T., et al., “Molecular Subtypes of Diffuse Large B‐Cell Lymphoma Arise by Distinct Genetic Pathways,” Proceedings of the National Academy of Sciences
105, no. 36 (september 2008): 13520–13525, 10.1073/pnas.0804295105.</cite> [<a href="https://doi.org/10.1073/pnas.0804295105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2533222/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18765795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences&amp;title=Molecular%20Subtypes%20of%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20Arise%20by%20Distinct%20Genetic%20Pathways&amp;author=G.%20Lenz&amp;author=G.%20W.%20Wright&amp;author=N.%20C.%20T.%20Emre&amp;volume=105&amp;issue=36&amp;publication_year=september%202008&amp;pages=13520-13525&amp;pmid=18765795&amp;doi=10.1073/pnas.0804295105&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0013">
<span class="label">13.</span><cite>
Dunleavy K., Pittaluga S., Maeda L. S., et al., “Dose‐Adjusted EPOCH‐Rituximab Therapy in Primary Mediastinal B‐Cell Lymphoma,” New England Journal of Medicine
368, no. 15 (avril 2013): 1408–1416, 10.1056/NEJMoa1214561.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1214561" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4568999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23574119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Dose%E2%80%90Adjusted%20EPOCH%E2%80%90Rituximab%20Therapy%20in%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma&amp;author=K.%20Dunleavy&amp;author=S.%20Pittaluga&amp;author=L.%20S.%20Maeda&amp;volume=368&amp;issue=15&amp;publication_year=avril%202013&amp;pages=1408-1416&amp;pmid=23574119&amp;doi=10.1056/NEJMoa1214561&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0014">
<span class="label">14.</span><cite>
Camus V., Rossi C., Sesques P., et al., “Outcomes After First‐Line Immunochemotherapy for Primary Mediastinal B‐Cell Lymphoma: A LYSA Study,” Blood Advances
5, no. 19 (october 2021): 3862–3872, 10.1182/bloodadvances.2021004778.
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2021004778" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8679665/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34461634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Advances&amp;title=Outcomes%20After%20First%E2%80%90Line%20Immunochemotherapy%20for%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma:%20A%20LYSA%20Study&amp;author=V.%20Camus&amp;author=C.%20Rossi&amp;author=P.%20Sesques&amp;volume=5&amp;issue=19&amp;publication_year=october%202021&amp;pages=3862-3872&amp;pmid=34461634&amp;doi=10.1182/bloodadvances.2021004778&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0015">
<span class="label">15.</span><cite>
Giulino‐Roth L., O'Donohue T., Chen Z., et al., “Outcomes of Adults and Children With Primary Mediastinal B‐Cell Lymphoma Treated With Dose‐Adjusted EPOCH‐R,” British Journal of Haematology
179, no. 5 (2017): 739–747, 10.1111/bjh.14951.
</cite> [<a href="https://doi.org/10.1111/bjh.14951" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6650639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29082519/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Haematology&amp;title=Outcomes%20of%20Adults%20and%20Children%20With%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma%20Treated%20With%20Dose%E2%80%90Adjusted%20EPOCH%E2%80%90R&amp;author=L.%20Giulino%E2%80%90Roth&amp;author=T.%20O'Donohue&amp;author=Z.%20Chen&amp;volume=179&amp;issue=5&amp;publication_year=2017&amp;pages=739-747&amp;pmid=29082519&amp;doi=10.1111/bjh.14951&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0016">
<span class="label">16.</span><cite>
Messmer M., Tsai H. L., Varadhan R., et al., “R‐CHOP Without Radiation in Frontline Management of Primary Mediastinal B‐Cell Lymphoma,” Leukemia and Lymphoma
60, no. 5 (avril 2019): 1261–1265, 10.1080/10428194.2018.1519812.
</cite> [<a href="https://doi.org/10.1080/10428194.2018.1519812" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6472975/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30656983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia%20and%20Lymphoma&amp;title=R%E2%80%90CHOP%20Without%20Radiation%20in%20Frontline%20Management%20of%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma&amp;author=M.%20Messmer&amp;author=H.%20L.%20Tsai&amp;author=R.%20Varadhan&amp;volume=60&amp;issue=5&amp;publication_year=avril%202019&amp;pages=1261-1265&amp;pmid=30656983&amp;doi=10.1080/10428194.2018.1519812&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0017">
<span class="label">17.</span><cite>
Pinnix C. C., Dabaja B., Ahmed M. A., et al., “Single‐Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18fluorodeoxyglucose Positron Emission Tomography,” International Journal of Radiation Oncology, Biology, Physics
92, no. 1 (mai 2015): 113–121, 10.1016/j.ijrobp.2015.02.006.
</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2015.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4418191/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25863759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Radiation%20Oncology,%20Biology,%20Physics&amp;title=Single%E2%80%90Institution%20Experience%20in%20the%20Treatment%20of%20Primary%20Mediastinal%20B%20Cell%20Lymphoma%20Treated%20With%20Immunochemotherapy%20in%20the%20Setting%20of%20Response%20Assessment%20by%2018fluorodeoxyglucose%20Positron%20Emission%20Tomography&amp;author=C.%20C.%20Pinnix&amp;author=B.%20Dabaja&amp;author=M.%20A.%20Ahmed&amp;volume=92&amp;issue=1&amp;publication_year=mai%202015&amp;pages=113-121&amp;pmid=25863759&amp;doi=10.1016/j.ijrobp.2015.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0018">
<span class="label">18.</span><cite>
Martelli M., Zucca E., Botto B., et al., “Impact of Different Induction Regimens on the Outcome of Primary Mediastinal B Cell Lymphoma in the Prospective Ielsg 37 Trial,” Hematological Oncology
39, no. S2 (juin 2021): 49–2879, 10.1002/hon.49_2879.</cite> [<a href="https://doi.org/10.1002/hon.49_2879" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematological%20Oncology&amp;title=Impact%20of%20Different%20Induction%20Regimens%20on%20the%20Outcome%20of%20Primary%20Mediastinal%20B%20Cell%20Lymphoma%20in%20the%20Prospective%20Ielsg%2037%20Trial&amp;author=M.%20Martelli&amp;author=E.%20Zucca&amp;author=B.%20Botto&amp;volume=39&amp;issue=S2&amp;publication_year=juin%202021&amp;pages=49-2879&amp;doi=10.1002/hon.49_2879&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0019">
<span class="label">19.</span><cite>
Sibon D., Gisselbrecht C., Molina T. J., et al., “Outcome of Patients With Primary Mediastinal Large B‐Cell Lymphoma After R‐CHOP21, R‐CHOP14 and R‐ACVBP: A Pooled Analysis of Clinical Trials From Lysa,” Blood
140, no. Supplement 1 (november 2022): 1082–1084, 10.1182/blood-2022-166228.</cite> [<a href="https://doi.org/10.1182/blood-2022-166228" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Outcome%20of%20Patients%20With%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma%20After%20R%E2%80%90CHOP21,%20R%E2%80%90CHOP14%20and%20R%E2%80%90ACVBP:%20A%20Pooled%20Analysis%20of%20Clinical%20Trials%20From%20Lysa&amp;author=D.%20Sibon&amp;author=C.%20Gisselbrecht&amp;author=T.%20J.%20Molina&amp;volume=140&amp;issue=Supplement%201&amp;publication_year=november%202022&amp;pages=1082-1084&amp;doi=10.1182/blood-2022-166228&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0020">
<span class="label">20.</span><cite>
Davies A. J., Zucca E., Ceriani L., et al., “A Randomized Trial of Observation Versus Radiotherapy in Primary Mediastinal B‐Cell Lymphoma Patients With Complete Metabolic Response After Standard Immunochemotherapy,” Hematological Oncology
41, no. S2 (juin 2023): 48–50, 10.1002/hon.3163_19.37294957
</cite> [<a href="https://doi.org/10.1002/hon.3163_19" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematological%20Oncology&amp;title=A%20Randomized%20Trial%20of%20Observation%20Versus%20Radiotherapy%20in%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma%20Patients%20With%20Complete%20Metabolic%20Response%20After%20Standard%20Immunochemotherapy&amp;author=A.%20J.%20Davies&amp;author=E.%20Zucca&amp;author=L.%20Ceriani&amp;volume=41&amp;issue=S2&amp;publication_year=juin%202023&amp;pages=48-50&amp;doi=10.1002/hon.3163_19&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0021">
<span class="label">21.</span><cite>
Giri S., Bhatt V. R., Pathak R., Bociek R. G., Vose J. M., and Armitage J. O., “Role of Radiation Therapy in Primary Mediastinal Large B‐Cell Lymphoma in Rituximab Era: A US Population‐Based Analysis,” American Journal of Hematology
90, no. 11 (november 2015): 1052–1054, 10.1002/ajh.24172.
</cite> [<a href="https://doi.org/10.1002/ajh.24172" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26270899/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Hematology&amp;title=Role%20of%20Radiation%20Therapy%20in%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma%20in%20Rituximab%20Era:%20A%20US%20Population%E2%80%90Based%20Analysis&amp;author=S.%20Giri&amp;author=V.%20R.%20Bhatt&amp;author=R.%20Pathak&amp;author=R.%20G.%20Bociek&amp;author=J.%20M.%20Vose&amp;volume=90&amp;issue=11&amp;publication_year=november%202015&amp;pages=1052-1054&amp;pmid=26270899&amp;doi=10.1002/ajh.24172&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0022">
<span class="label">22.</span><cite>
Brusamolino E., Baio A., Orlandi E., et al., “Long‐Term Events in Adult Patients With Clinical Stage IA‐IIA Nonbulky Hodgkin’s Lymphoma Treated With Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single‐Institution 15‐Year Follow‐Up,” Clinical Cancer Research
12, no. 21 (november 2006): 6487–6493, 10.1158/1078-0432.CCR-06-1420.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-06-1420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17085663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Cancer%20Research&amp;title=Long%E2%80%90Term%20Events%20in%20Adult%20Patients%20With%20Clinical%20Stage%20IA%E2%80%90IIA%20Nonbulky%20Hodgkin%E2%80%99s%20Lymphoma%20Treated%20With%20Four%20Cycles%20of%20Doxorubicin,%20Bleomycin,%20Vinblastine,%20and%20Dacarbazine%20and%20Adjuvant%20Radiotherapy:%20A%20Single%E2%80%90Institution%2015%E2%80%90Year%20Follow%E2%80%90Up&amp;author=E.%20Brusamolino&amp;author=A.%20Baio&amp;author=E.%20Orlandi&amp;volume=12&amp;issue=21&amp;publication_year=november%202006&amp;pages=6487-6493&amp;pmid=17085663&amp;doi=10.1158/1078-0432.CCR-06-1420&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0023">
<span class="label">23.</span><cite>
Lagerlöf I., Fohlin H., Glimelius B., et al., “But Not Eliminated, Excess Long‐Term Morbidity in Stage I‐IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited‐Field Radiotherapy,” Journal of Clinical Oncology
40, no. 13 (mai 2022): 1487–1496, 10.1200/JCO.21.02407.
</cite> [<a href="https://doi.org/10.1200/JCO.21.02407" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9061145/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35077204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=But%20Not%20Eliminated,%20Excess%20Long%E2%80%90Term%20Morbidity%20in%20Stage%20I%E2%80%90IIA%20Hodgkin%20Lymphoma%20Treated%20With%20Doxorubicin,%20Bleomycin,%20Vinblastine,%20and%20Dacarbazine%20and%20Limited%E2%80%90Field%20Radiotherapy&amp;author=I.%20Lagerl%C3%B6f&amp;author=H.%20Fohlin&amp;author=B.%20Glimelius&amp;volume=40&amp;issue=13&amp;publication_year=mai%202022&amp;pages=1487-1496&amp;pmid=35077204&amp;doi=10.1200/JCO.21.02407&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0024">
<span class="label">24.</span><cite>
Cheah C. Y., Hofman M. S., Seymour J. F., et al., “The Utility and Limitations of (18)F‐Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography in Patients With Primary Mediastinal B‐Cell Lymphoma: Single Institution Experience and Literature Review,” Leukemia and Lymphoma
56, no. 1 (janvier 2015): 49–56, 10.3109/10428194.2014.910656.
</cite> [<a href="https://doi.org/10.3109/10428194.2014.910656" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24724780/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia%20and%20Lymphoma&amp;title=The%20Utility%20and%20Limitations%20of%20(18)F%E2%80%90Fluorodeoxyglucose%20Positron%20Emission%20Tomography%20With%20Computed%20Tomography%20in%20Patients%20With%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma:%20Single%20Institution%20Experience%20and%20Literature%20Review&amp;author=C.%20Y.%20Cheah&amp;author=M.%20S.%20Hofman&amp;author=J.%20F.%20Seymour&amp;volume=56&amp;issue=1&amp;publication_year=janvier%202015&amp;pages=49-56&amp;pmid=24724780&amp;doi=10.3109/10428194.2014.910656&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0025">
<span class="label">25.</span><cite>
Melani C., Advani R., Roschewski M., et al., “End‐of‐Treatment and Serial PET Imaging in Primary Mediastinal B‐Cell Lymphoma Following Dose‐Adjusted EPOCH‐R: A Paradigm Shift in Clinical Decision Making,” Haematologica
103, no. 8 (2018): 1337–1344, 10.3324/haematol.2018.192492.
</cite> [<a href="https://doi.org/10.3324/haematol.2018.192492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6068044/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29748435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=End%E2%80%90of%E2%80%90Treatment%20and%20Serial%20PET%20Imaging%20in%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma%20Following%20Dose%E2%80%90Adjusted%20EPOCH%E2%80%90R:%20A%20Paradigm%20Shift%20in%20Clinical%20Decision%20Making&amp;author=C.%20Melani&amp;author=R.%20Advani&amp;author=M.%20Roschewski&amp;volume=103&amp;issue=8&amp;publication_year=2018&amp;pages=1337-1344&amp;pmid=29748435&amp;doi=10.3324/haematol.2018.192492&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0026">
<span class="label">26.</span><cite>
Kuruvilla J., Pintilie M., Tsang R., et al., “Salvage Chemotherapy and Autologous Stem Cell Transplantation Are Inferior for Relapsed or Refractory Primary Mediastinal Large B‐Cell Lymphoma Compared With Diffuse Large B‐Cell Lymphoma,” Leukemia and Lymphoma
49, no. 7 (janvier 2008): 1329–1336, 10.1080/10428190802108870.
</cite> [<a href="https://doi.org/10.1080/10428190802108870" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18604722/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia%20and%20Lymphoma&amp;title=Salvage%20Chemotherapy%20and%20Autologous%20Stem%20Cell%20Transplantation%20Are%20Inferior%20for%20Relapsed%20or%20Refractory%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma%20Compared%20With%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=J.%20Kuruvilla&amp;author=M.%20Pintilie&amp;author=R.%20Tsang&amp;volume=49&amp;issue=7&amp;publication_year=janvier%202008&amp;pages=1329-1336&amp;pmid=18604722&amp;doi=10.1080/10428190802108870&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0027">
<span class="label">27.</span><cite>
Zinzani P. L., Santoro A., Gritti G., et al., “Nivolumab Combined With Brentuximab Vedotin for R/R Primary Mediastinal Large B‐Cell Lymphoma: A 3‐year Follow‐Up,” Blood Advances
7, no. 18 (september 2023): 5272–5280, 10.1182/bloodadvances.2023010254.
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2023010254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10500465/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37352266/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Advances&amp;title=Nivolumab%20Combined%20With%20Brentuximab%20Vedotin%20for%20R/R%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma:%20A%203%E2%80%90year%20Follow%E2%80%90Up&amp;author=P.%20L.%20Zinzani&amp;author=A.%20Santoro&amp;author=G.%20Gritti&amp;volume=7&amp;issue=18&amp;publication_year=september%202023&amp;pages=5272-5280&amp;pmid=37352266&amp;doi=10.1182/bloodadvances.2023010254&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0028">
<span class="label">28.</span><cite>
Armand P., Rodig S., Melnichenko V., et al., “Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B‐Cell Lymphoma,” Journal of Clinical Oncology
37, no. 34 (2019): 3291–3299, 10.1200/JCO.19.01389.
</cite> [<a href="https://doi.org/10.1200/JCO.19.01389" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6881098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31609651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Pembrolizumab%20in%20Relapsed%20or%20Refractory%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=P.%20Armand&amp;author=S.%20Rodig&amp;author=V.%20Melnichenko&amp;volume=37&amp;issue=34&amp;publication_year=2019&amp;pages=3291-3299&amp;pmid=31609651&amp;doi=10.1200/JCO.19.01389&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0029">
<span class="label">29.</span><cite>
Crombie J. L., Nastoupil L. J., Redd R. A., et al., “Real‐World Outcomes of Axicabtagene Ciloleucel in Adult Patients With Primary Mediastinal B‐Cell Lymphoma,” Blood Advances (september 2021): 2021004880, 10.1182/bloodadvances.2021004880.</cite> [<a href="https://doi.org/10.1182/bloodadvances.2021004880" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8945592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34474474/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Advances&amp;title=Real%E2%80%90World%20Outcomes%20of%20Axicabtagene%20Ciloleucel%20in%20Adult%20Patients%20With%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma&amp;author=J.%20L.%20Crombie&amp;author=L.%20J.%20Nastoupil&amp;author=R.%20A.%20Redd&amp;publication_year=september%202021&amp;pages=2021004880&amp;pmid=34474474&amp;doi=10.1182/bloodadvances.2021004880&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0030">
<span class="label">30.</span><cite>
Chiappella A., Casadei B., Chiusolo P., et al., “Axicabtagene Ciloleucel Treatment is More Effective in Primary Mediastinal Large B‐Cell Lymphomas Than in Diffuse Large B‐Cell Lymphomas: The Italian CART‐SIE Study,” Leukemia
38, no. 5 (mai 2024): 1107–1114, 10.1038/s41375-024-02213-x.
</cite> [<a href="https://doi.org/10.1038/s41375-024-02213-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11073993/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38459167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Axicabtagene%20Ciloleucel%20Treatment%20is%20More%20Effective%20in%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphomas%20Than%20in%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphomas:%20The%20Italian%20CART%E2%80%90SIE%20Study&amp;author=A.%20Chiappella&amp;author=B.%20Casadei&amp;author=P.%20Chiusolo&amp;volume=38&amp;issue=5&amp;publication_year=mai%202024&amp;pages=1107-1114&amp;pmid=38459167&amp;doi=10.1038/s41375-024-02213-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0031">
<span class="label">31.</span><cite>
Campo E., Jaffe E. S., Cook J. R., et al., “The International Consensus Classification of Mature Lymphoid Neoplasms: A Report From the Clinical Advisory Committee,” Blood
140, no. 11 (september 2022): 1229–1253, 10.1182/blood.2022015851.
</cite> [<a href="https://doi.org/10.1182/blood.2022015851" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9479027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35653592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20International%20Consensus%20Classification%20of%20Mature%20Lymphoid%20Neoplasms:%20A%20Report%20From%20the%20Clinical%20Advisory%20Committee&amp;author=E.%20Campo&amp;author=E.%20S.%20Jaffe&amp;author=J.%20R.%20Cook&amp;volume=140&amp;issue=11&amp;publication_year=september%202022&amp;pages=1229-1253&amp;pmid=35653592&amp;doi=10.1182/blood.2022015851&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0032">
<span class="label">32.</span><cite>
Swerdlow S. H., Campo E., Pileri S. A., et al., “The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms,” Blood
127, no. 20 (mai 2016): 2375–2390, 10.1182/blood-2016-01-643569.
</cite> [<a href="https://doi.org/10.1182/blood-2016-01-643569" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4874220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26980727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%202016%20Revision%20of%20the%20World%20Health%20Organization%20Classification%20of%20Lymphoid%20Neoplasms&amp;author=S.%20H.%20Swerdlow&amp;author=E.%20Campo&amp;author=S.%20A.%20Pileri&amp;volume=127&amp;issue=20&amp;publication_year=mai%202016&amp;pages=2375-2390&amp;pmid=26980727&amp;doi=10.1182/blood-2016-01-643569&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0033">
<span class="label">33.</span><cite>
Campo E., Swerdlow S. H., Harris N. L., et al., “The 2008 WHO Classification of Lymphoid Neoplasms and Beyond: Evolving Concepts and Practical Applications,” Blood
117, no. 19 (mai 2011): 5019–5032, 10.1182/blood-2011-01-293050.
</cite> [<a href="https://doi.org/10.1182/blood-2011-01-293050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3109529/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21300984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%202008%20WHO%20Classification%20of%20Lymphoid%20Neoplasms%20and%20Beyond:%20Evolving%20Concepts%20and%20Practical%20Applications&amp;author=E.%20Campo&amp;author=S.%20H.%20Swerdlow&amp;author=N.%20L.%20Harris&amp;volume=117&amp;issue=19&amp;publication_year=mai%202011&amp;pages=5019-5032&amp;pmid=21300984&amp;doi=10.1182/blood-2011-01-293050&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0034">
<span class="label">34.</span><cite>
Meignan M., Sasanelli M., Casasnovas R. O., et al., “Metabolic Tumour Volumes Measured at Staging in Lymphoma: Methodological Evaluation on Phantom Experiments and Patients,” European Journal of Nuclear Medicine and Molecular Imaging
41, no. 6 (juin 2014): 1113–1122, 10.1007/s00259-014-2705-y.
</cite> [<a href="https://doi.org/10.1007/s00259-014-2705-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24570094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Nuclear%20Medicine%20and%20Molecular%20Imaging&amp;title=Metabolic%20Tumour%20Volumes%20Measured%20at%20Staging%20in%20Lymphoma:%20Methodological%20Evaluation%20on%20Phantom%20Experiments%20and%20Patients&amp;author=M.%20Meignan&amp;author=M.%20Sasanelli&amp;author=R.%20O.%20Casasnovas&amp;volume=41&amp;issue=6&amp;publication_year=juin%202014&amp;pages=1113-1122&amp;pmid=24570094&amp;doi=10.1007/s00259-014-2705-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0035">
<span class="label">35.</span><cite>
Cheson B. D., Fisher R. I., Barrington S. F., et al., “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non‐Hodgkin Lymphoma: The Lugano Classification,” Journal of Clinical Oncology Officical Journal of American Society of Clinical Oncology
32, no. 27 (september 2014): 3059–3068, 10.1200/JCO.2013.54.8800.</cite> [<a href="https://doi.org/10.1200/JCO.2013.54.8800" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4979083/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25113753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology%20Officical%20Journal%20of%20American%20Society%20of%20Clinical%20Oncology&amp;title=Recommendations%20for%20Initial%20Evaluation,%20Staging,%20and%20Response%20Assessment%20of%20Hodgkin%20and%20Non%E2%80%90Hodgkin%20Lymphoma:%20The%20Lugano%20Classification&amp;author=B.%20D.%20Cheson&amp;author=R.%20I.%20Fisher&amp;author=S.%20F.%20Barrington&amp;volume=32&amp;issue=27&amp;publication_year=september%202014&amp;pages=3059-3068&amp;pmid=25113753&amp;doi=10.1200/JCO.2013.54.8800&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0036">
<span class="label">36.</span><cite>
Shah N. N., Szabo A., Huntington S. F., et al., “R‐ CHOP Versus Dose‐Adjusted R‐ EPOCH in Frontline Management of Primary Mediastinal B‐cell Lymphoma: A Multi‐Centre Analysis,” British Journal of Haematology
180, no. 4 (2018): 534–544, 10.1111/bjh.15051.
</cite> [<a href="https://doi.org/10.1111/bjh.15051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29265182/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Haematology&amp;title=R%E2%80%90%20CHOP%20Versus%20Dose%E2%80%90Adjusted%20R%E2%80%90%20EPOCH%20in%20Frontline%20Management%20of%20Primary%20Mediastinal%20B%E2%80%90cell%20Lymphoma:%20A%20Multi%E2%80%90Centre%20Analysis&amp;author=N.%20N.%20Shah&amp;author=A.%20Szabo&amp;author=S.%20F.%20Huntington&amp;volume=180&amp;issue=4&amp;publication_year=2018&amp;pages=534-544&amp;pmid=29265182&amp;doi=10.1111/bjh.15051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0037">
<span class="label">37.</span><cite>
Stepanishyna Y., Skrypets T., Novosad O., Pastushenko I., and Kryachok I., et al., “DA‐EPOCH‐R VS R‐CHOP in Patients With Primary Mediastinal Large B‐Cell Lymphoma: Results of Prospective Randomized Ukrainian Multicenter Study,” Blood
136, no. Supplement 1 (november 2020): 9, 10.1182/blood-2020-141348.</cite> [<a href="https://doi.org/10.1182/blood-2020-141348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=DA%E2%80%90EPOCH%E2%80%90R%20VS%20R%E2%80%90CHOP%20in%20Patients%20With%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma:%20Results%20of%20Prospective%20Randomized%20Ukrainian%20Multicenter%20Study&amp;author=Y.%20Stepanishyna&amp;author=T.%20Skrypets&amp;author=O.%20Novosad&amp;author=I.%20Pastushenko&amp;author=I.%20Kryachok&amp;volume=136&amp;issue=Supplement%201&amp;publication_year=november%202020&amp;pages=9&amp;doi=10.1182/blood-2020-141348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0038">
<span class="label">38.</span><cite>
Burke G. A. A., Minard‐Colin V., Aupérin A., et al., “Dose‐Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B‐Cell Lymphoma: A Multicenter Phase II Trial,” Journal of Clinical Oncology
39, no. 33 (november 2021): 3716–3724, 10.1200/JCO.21.00920.
</cite> [<a href="https://doi.org/10.1200/JCO.21.00920" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9150887/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34570655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Dose%E2%80%90Adjusted%20Etoposide,%20Doxorubicin,%20and%20Cyclophosphamide%20With%20Vincristine%20and%20Prednisone%20Plus%20Rituximab%20Therapy%20in%20Children%20and%20Adolescents%20With%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma:%20A%20Multicenter%20Phase%20II%20Trial&amp;author=G.%20A.%20A.%20Burke&amp;author=V.%20Minard%E2%80%90Colin&amp;author=A.%20Aup%C3%A9rin&amp;volume=39&amp;issue=33&amp;publication_year=november%202021&amp;pages=3716-3724&amp;pmid=34570655&amp;doi=10.1200/JCO.21.00920&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0039">
<span class="label">39.</span><cite>
Santarsieri A., Bennett R., Hopkins D., et al., “R‐DA‐EPOCH Treatment is Highly Effective Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A Real‐World Multi‐Centre Retrospective Evaluation,” Blood
140, no. Supplement 1 (november 2022): 9551–9553, 10.1182/blood-2022-166181.</cite> [<a href="https://doi.org/10.1182/blood-2022-166181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=R%E2%80%90DA%E2%80%90EPOCH%20Treatment%20is%20Highly%20Effective%20Therapy%20for%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma:%20A%20Real%E2%80%90World%20Multi%E2%80%90Centre%20Retrospective%20Evaluation&amp;author=A.%20Santarsieri&amp;author=R.%20Bennett&amp;author=D.%20Hopkins&amp;volume=140&amp;issue=Supplement%201&amp;publication_year=november%202022&amp;pages=9551-9553&amp;doi=10.1182/blood-2022-166181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0040">
<span class="label">40.</span><cite>
Knörr F., Zimmermann M., Attarbaschi A., et al., “Dose‐Adjusted EPOCH‐Rituximab or Intensified B‐NHL Therapy for Pediatric Primary Mediastinal Large B‐Cell Lymphoma,” Haematologica
106, no. 12 (2021): 3232–3235, 10.3324/haematol.2021.278971.
</cite> [<a href="https://doi.org/10.3324/haematol.2021.278971" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8634171/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34498443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Dose%E2%80%90Adjusted%20EPOCH%E2%80%90Rituximab%20or%20Intensified%20B%E2%80%90NHL%20Therapy%20for%20Pediatric%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=F.%20Kn%C3%B6rr&amp;author=M.%20Zimmermann&amp;author=A.%20Attarbaschi&amp;volume=106&amp;issue=12&amp;publication_year=2021&amp;pages=3232-3235&amp;pmid=34498443&amp;doi=10.3324/haematol.2021.278971&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0041">
<span class="label">41.</span><cite>
Wilson W. H., Jung S. H., Porcu P., et al., “A Cancer and Leukemia Group B Multi‐Center Study of DA‐EPOCH‐Rituximab in Untreated Diffuse Large B‐Cell Lymphoma With Analysis of Outcome by Molecular Subtype,” Haematologica
97, no. 5 (mai 2012): 758–765, 10.3324/haematol.2011.056531.
</cite> [<a href="https://doi.org/10.3324/haematol.2011.056531" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3342980/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22133772/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=A%20Cancer%20and%20Leukemia%20Group%20B%20Multi%E2%80%90Center%20Study%20of%20DA%E2%80%90EPOCH%E2%80%90Rituximab%20in%20Untreated%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20With%20Analysis%20of%20Outcome%20by%20Molecular%20Subtype&amp;author=W.%20H.%20Wilson&amp;author=S.%20H.%20Jung&amp;author=P.%20Porcu&amp;volume=97&amp;issue=5&amp;publication_year=mai%202012&amp;pages=758-765&amp;pmid=22133772&amp;doi=10.3324/haematol.2011.056531&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0042">
<span class="label">42.</span><cite>
Wilson W. H., Dunleavy K., Pittaluga S., et al., “Phase II Study of Dose‐Adjusted EPOCH and Rituximab in Untreated Diffuse Large B‐Cell Lymphoma With Analysis of Germinal Center and Post‐Germinal Center Biomarkers,” Journal of Clinical Oncology Officical Journal of American Society of Clinical Oncology
26, no. 16 (juin 2008): 2717–2724, 10.1200/JCO.2007.13.1391.</cite> [<a href="https://doi.org/10.1200/JCO.2007.13.1391" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2409217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18378569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology%20Officical%20Journal%20of%20American%20Society%20of%20Clinical%20Oncology&amp;title=Phase%20II%20Study%20of%20Dose%E2%80%90Adjusted%20EPOCH%20and%20Rituximab%20in%20Untreated%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20With%20Analysis%20of%20Germinal%20Center%20and%20Post%E2%80%90Germinal%20Center%20Biomarkers&amp;author=W.%20H.%20Wilson&amp;author=K.%20Dunleavy&amp;author=S.%20Pittaluga&amp;volume=26&amp;issue=16&amp;publication_year=juin%202008&amp;pages=2717-2724&amp;pmid=18378569&amp;doi=10.1200/JCO.2007.13.1391&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0043">
<span class="label">43.</span><cite>
Lazarovici J., Terroir M., Arfi‐Rouche J., et al., “Poor Predictive Value of Positive Interim FDG‐PET/CT in Primary Mediastinal Large B‐Cell Lymphoma,” European Journal of Nuclear Medicine and Molecular Imaging
44, no. 12 (november 2017): 2018–2024, 10.1007/s00259-017-3758-5.
</cite> [<a href="https://doi.org/10.1007/s00259-017-3758-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28634685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Nuclear%20Medicine%20and%20Molecular%20Imaging&amp;title=Poor%20Predictive%20Value%20of%20Positive%20Interim%20FDG%E2%80%90PET/CT%20in%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=J.%20Lazarovici&amp;author=M.%20Terroir&amp;author=J.%20Arfi%E2%80%90Rouche&amp;volume=44&amp;issue=12&amp;publication_year=november%202017&amp;pages=2018-2024&amp;pmid=28634685&amp;doi=10.1007/s00259-017-3758-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0044">
<span class="label">44.</span><cite>
Aoki T., Izutsu K., Suzuki R., et al., “Prognostic Significance of Pleural or Pericardial Effusion and the Implication of Optimal Treatment in Primary Mediastinal Large B‐Cell Lymphoma: A Multicenter Retrospective Study in Japan,” Haematologica
99, no. 12 (2014): 1817–1825, 10.3324/haematol.2014.111203.
</cite> [<a href="https://doi.org/10.3324/haematol.2014.111203" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4258760/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25216682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Prognostic%20Significance%20of%20Pleural%20or%20Pericardial%20Effusion%20and%20the%20Implication%20of%20Optimal%20Treatment%20in%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma:%20A%20Multicenter%20Retrospective%20Study%20in%20Japan&amp;author=T.%20Aoki&amp;author=K.%20Izutsu&amp;author=R.%20Suzuki&amp;volume=99&amp;issue=12&amp;publication_year=2014&amp;pages=1817-1825&amp;pmid=25216682&amp;doi=10.3324/haematol.2014.111203&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0045">
<span class="label">45.</span><cite>
Avivi I., Boumendil A., Finel H., et al., “Autologous Stem Cell Transplantation for Primary Mediastinal B‐Cell Lymphoma: Long‐Term Outcome and Role of Post‐transplant Radiotherapy. A Report of the European Society for Blood and Marrow Transplantation,” Bone Marrow Transplantation
53, no. 8 (2018): 1001–1009, 10.1038/s41409-017-0063-7.
</cite> [<a href="https://doi.org/10.1038/s41409-017-0063-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29463854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bone%20Marrow%20Transplantation&amp;title=Autologous%20Stem%20Cell%20Transplantation%20for%20Primary%20Mediastinal%20B%E2%80%90Cell%20Lymphoma:%20Long%E2%80%90Term%20Outcome%20and%20Role%20of%20Post%E2%80%90transplant%20Radiotherapy.%20A%20Report%20of%20the%20European%20Society%20for%20Blood%20and%20Marrow%20Transplantation&amp;author=I.%20Avivi&amp;author=A.%20Boumendil&amp;author=H.%20Finel&amp;volume=53&amp;issue=8&amp;publication_year=2018&amp;pages=1001-1009&amp;pmid=29463854&amp;doi=10.1038/s41409-017-0063-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0046">
<span class="label">46.</span><cite>
Vardhana S., Hamlin P. A., Yang J., et al., “Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated With Second‐Line Therapy and Intent to Transplant,” Biology of Blood and Marrow Transplantation
24, no. 10 (october 2018): 2133–2138, 10.1016/j.bbmt.2018.06.009.
</cite> [<a href="https://doi.org/10.1016/j.bbmt.2018.06.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7517639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29909154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biology%20of%20Blood%20and%20Marrow%20Transplantation&amp;title=Outcomes%20of%20Relapsed%20and%20Refractory%20Primary%20Mediastinal%20(Thymic)%20Large%20B%20Cell%20Lymphoma%20Treated%20With%20Second%E2%80%90Line%20Therapy%20and%20Intent%20to%20Transplant&amp;author=S.%20Vardhana&amp;author=P.%20A.%20Hamlin&amp;author=J.%20Yang&amp;volume=24&amp;issue=10&amp;publication_year=october%202018&amp;pages=2133-2138&amp;pmid=29909154&amp;doi=10.1016/j.bbmt.2018.06.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0047">
<span class="label">47.</span><cite>
Renaud L., Wencel J., Pagès A., et al., “Nivolumab Combined With Brentuximab Vedotin With or Without Mediastinal Radiotherapy for Relapsed/refractory Primary Mediastinal Large B‐Cell Lymphoma,” Haematologica (mai 2024): 3019, 10.3324/haematol.2023.284689.
</cite> [<a href="https://doi.org/10.3324/haematol.2023.284689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11367187/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38695142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Nivolumab%20Combined%20With%20Brentuximab%20Vedotin%20With%20or%20Without%20Mediastinal%20Radiotherapy%20for%20Relapsed/refractory%20Primary%20Mediastinal%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=L.%20Renaud&amp;author=J.%20Wencel&amp;author=A.%20Pag%C3%A8s&amp;publication_year=mai%202024&amp;pages=3019&amp;pmid=38695142&amp;doi=10.3324/haematol.2023.284689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70060-bib-0048">
<span class="label">48.</span><cite>
Schubert M.‐L., Bethge W. A., Ayuk F. A., et al., “Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably With Those in DLBCL: A GLA/DRST Registry Study,” Blood Advances
7, no. 20 (october 2023): 6191–6195, 10.1182/bloodadvances.2023011203.
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2023011203" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10582836/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37603595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Advances&amp;title=Outcomes%20of%20Axicabtagene%20Ciloleucel%20in%20PMBCL%20Compare%20Favorably%20With%20Those%20in%20DLBCL:%20A%20GLA/DRST%20Registry%20Study&amp;author=M.%E2%80%90L.%20Schubert&amp;author=W.%20A.%20Bethge&amp;author=F.%20A.%20Ayuk&amp;volume=7&amp;issue=20&amp;publication_year=october%202023&amp;pages=6191-6195&amp;pmid=37603595&amp;doi=10.1182/bloodadvances.2023011203&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>Supporting Information S1</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11993899/bin/HON-43-e70060-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70060-s001.docx</a><sup> (121.5KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Hematological Oncology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/hon.70060"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/HON-43-e70060.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (981.5 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11993899/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11993899/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11993899%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11993899/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11993899/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11993899/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40221881/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11993899/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40221881/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11993899/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11993899/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="JkrMqW3TYryMVVzqKLptgtU9xN8awGa3gX0GKgixPq167akp7DXKdhuP8PJMuA1T">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
